What’s Driving Growth in the Pulmonary Or Respiratory Drug Delivery Market? Insights into Key Trends and Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the pulmonary or respiratory drug delivery market grown in recent years?
In recent times, the size of the pulmonary or respiratory drug delivery market has witnessed robust growth. It is expected to increase from $69.83 billion in 2024 to $76.38 billion in 2025 with a compound annual growth rate (CAGR) of 9.4%. The increasing occurrence of asthma, the growing use of advanced inhalation devices, the global expansion in healthcare spending, heightened awareness of respiratory illnesses, and the increasing rate of allergies are key factors that contributed to market growth in the historic period.
How is the pulmonary or respiratory drug delivery market size expected to evolve during the forecast period?
The market size for pulmonary or respiratory drug delivery is anticipated to witness substantial growth in the forthcoming years. By 2029, it is expected to escalate to $107.85 billion, expanding at a compound annual growth rate (CAGR) of 9.0%. Various factors contributing to this anticipated growth during the projection period include increased demand for individualized treatment, higher incidence of long-term respiratory illnesses, rising focus on telehealth, amplified healthcare infrastructure investments, and e-commerce expansion for pharmaceutical goods. The forecast period is also set to see emerging trends such as progress in particle engineering, enhanced nebulizer developments, evolution of liposomal formulations, advancements in computational fluid dynamics, and the introduction of intelligent inhalers.
Get your pulmonary or respiratory drug delivery market report here!
Which key drivers are propelling the pulmonary or respiratory drug delivery market’s growth?
The growth of the pulmonary or respiratory drug delivery market is predicted to be spurred by the rising incidence of pneumonia. Pneumonia manifests as a lung infection, resulting in the inflammation of air sacs and possibly leading to accumulation of fluid or pus, which can cause fever, cough, and difficulties in breathing. There is an escalation in pneumonia prevalence due to factors including ageing demographics, compromised immune systems, respiratory infections, air pollution, smoking, and burgeoning antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery provides beneficial aid to pneumonia patients by delivering medications such as antibiotics, bronchodilators, and anti-inflammatory drugs directly to the lungs. This targeted approach promotes quicker and more effective symptom relief, inflammation reduction, infection clearance and enhancement of respiratory functionality, aiding in an accelerated recovery while thwarting any potential complications. For example, as stated by the Centre for Tropical Medicine and Global Health, a UK healthcare research leader, pneumonia cases in Kenya noticed a huge leap, with the count touching 793,864 in 2022/2023 in November 2023. As such, the escalating numbers of pneumonia patients propels the growth of the pulmonary or respiratory drug delivery market.
What are the market segments in the pulmonary or respiratory drug delivery industry?
The pulmonary or respiratory drug delivery market covered in this report is segmented –
1) By Product: Formulation Type, Device Type
2) By Canister Type: Plain Canister, Coated Canister
3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications
4) By End-User: Hospitals, Clinics, Home Care Settings
Subsegments:
1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays
2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp
Which leading companies are shaping the growth of the pulmonary or respiratory drug delivery market?
Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc
What emerging trends are influencing the growth of the pulmonary or respiratory drug delivery market?
Major companies operating in the pulmonary or respiratory drug delivery market are focusing on technological advancements such as complex drug delivery systems that enhance treatment efficacy and patient compliance. Complex drug delivery systems are advanced technologies that enhance the targeted delivery and controlled release of therapeutic agents, improving drug efficacy and patient outcomes. For instance, in July 2023, Viatris Inc., a US-based healthcare company that manufactures generic and branded medicines and Kindeva Drug Delivery L.P., a US-based company that offers drug delivery launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, an inhalation aerosol approved by the Food and Drug Administration, a US-based government agency. This is the first generic version of AstraZeneca’s Symbicort and a metered-dose inhaler that combines budesonide and formoterol for treating asthma and chronic obstructive pulmonary disease. It is available in two strengths of 80 micrograms and 160 micrograms with 4.5 micrograms of formoterol.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20939
Which geographic areas are influencing the growth of the pulmonary or respiratory drug delivery market?
North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Pulmonary Arterial Hypertension Global Market Report 2025
https://thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025
Idiopathic Pulmonary Fibrosis Global Global Market Report 2025
https://thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
